Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed a Current Report on Form 8-K on July 28, 2020, announcing the entry into a Material Definitive Agreement. The Company, a biopharmaceutical firm, secured a new credit facility to support its operations and development milestones.
Key Financial Metrics and Transaction Details
- Total Facility Size: Up to $50,000,000 in term loans.
- Initial Funding: $20,000,000 funded on the Closing Date (July 28, 2020), net of a $375,000 facility fee.
- Future Tranches:
- Second Tranche: $20,000,000 available by September 30, 2020, subject to milestones.
- Third Tranche: $10,000,000 available by March 31, 2022, subject to milestones.
- Interest Rate: Variable, greater of 8.5% or Prime Rate + 5.25% (subject to a 25 basis point step-down upon second tranche funding).
- Maturity Date: August 1, 2024.
- Repayment Terms: Interest-only payments until September 1, 2022 (or March 1, 2023 if third tranche drawn), followed by amortization. A final payment of 5.95% of the aggregate original principal is due upon final payment or prepayment.
- Equity Components:
- Conversion Option: Lenders may convert up to $5,000,000 of principal into common stock at $9.40 per share.
- Warrants: Issued for 3.00% of the principal amount per tranche at an exercise price of $6.96. The initial tranche resulted in a warrant for 86,206 shares.
Material Changes and Covenants
This filing represents a significant change in the Company's capital structure, introducing new debt obligations and potential equity dilution. The agreement includes restrictive covenants limiting additional indebtedness, liens, mergers, and distributions.
Liquidity Covenants:
- If certain milestones are not met before the second tranche, the Company must maintain unrestricted cash of at least $10,000,000 (waived if market cap > $200 million).
- If milestones are not met after the second tranche, the Company must maintain unrestricted cash equal to the aggregate principal amount of outstanding loans (waived if market cap > $500 million).
Outlook, Risks, and Contingencies
Management Commentary: The Company entered this agreement to secure funding for its development pipeline, with future funding contingent on achieving regulatory and developmental milestones.
Risks and Contingencies:
- Default Provisions: Events of default include payment defaults, covenant breaches, change of control, or material adverse effects. Default triggers an additional 5% per annum interest rate and immediate acceleration of debt.
- Prepayment Penalties: Mandatory prepayment is required upon a change of control. Voluntary prepayment incurs fees ranging from 1% to 3% depending on the timing relative to the funding date.
- Collateral: The loan is secured by a lien on substantially all personal property (excluding intellectual property) and the Company's equity interests in subsidiaries.
Investor Verification Checklist
- Verify the Company's current cash position against the $10,000,000 minimum liquidity covenant requirement.
- Confirm the status of regulatory and developmental milestones required to access the remaining $30,000,000 in funding.
- Assess the potential dilution impact of the $5,000,000 conversion option and the issued warrants.
- Review the Company's market capitalization to determine if liquidity covenants are currently waived.
- Examine the specific milestones defined in the Loan Agreement (Exhibit 10.1) to gauge the likelihood of future tranche funding.